Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Underprescribing Adds to Mortality, Hospitalization for Oldest Patients

Will Boggs, MD  |  July 21, 2016

NEW YORK (Reuters Health)—Inappropriate underprescribing of medications is associated with increased mortality and hospitalization rates among community-dwelling adults aged 80 years and older, researchers from Belgium report.

“Patients with five or more medications (a standard cut-off used for polypharmacy) can have a well-tailored and balanced medication therapy with an acceptable risk for adverse events,” Dr. Maarten Wauters from Ghent University in Belgium tells Reuters Health.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Yet, in contrast,” he adds, “patients with just a few medications could be at risk missing essential and beneficial medications. This is pressing us to carefully balance the benefit and risk of each drug on the list of older adults.”

Dr. Wauters and colleagues investigated the prevalence of inappropriate prescribing and its possible associations with mortality and hospitalization after 18 months among 503 community-dwelling patients aged 80 and over in the Belfrail-Med cohort.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

They assessed prescribing with the clinically oriented Screening Tool for Older Person’s Prescriptions (STOPP-2 criteria) for misuse and the Screening Tool to Alert doctors to Write Treatment (START-2) for underuse.

The average number of medications among these participants was 5.4 (range, 0–16), and 57.7% of the population had received at least five medications, according to the July 18th British Journal of Clinical Pharmacology online report.

Two-thirds of the population had underuse, 56.1% had misuse, and only 17.1% had neither underuse nor misuse. Four in 10 participants (40.2%) had a combination of underuse with misuse.

The overall mortality rate after 18 months was 8.9%, and the hospitalization rate was 31%. Survival rates were 97% with no underuse, 96% with low underuse, and 88% with high underuse. Survival free of hospitalization after one year was 85% with no underuse, 81% with low underuse and 59% with high underuse.

Mortality and hospitalization rates did not differ according to category of misuse, the researchers note, but the study may have been underpowered to identify these relationships.

In multivariate analysis, every additional underused medication was associated with a 39% increased risk for mortality and a 26% increased risk for hospitalization after 18 months.

High underuse (three or more “missing” medications) was associated with a 2.9-fold increased risk for mortality and a 2.1-fold risk for hospitalization, compared with no underuse.

“Assessing misuse and underuse continuously, and (preferably) in a multidisciplinary way involving pharmacists, nurses, or clinical pharmacologists, can help prescribers and pharmacists to adapt the medication regime to the patient’s context,” Dr. Wauters says. “Clinical pharmacologists can aid prescribers as well, by setting up electronic systems for monitoring the quality of prescribing, using evidence-based criteria of potentially inappropriate prescribing.”

Page: 1 2 | Single Page
Share: 

Filed under:Drug Updates Tagged with:elderlyMedicationprescription drug

Related Articles

    Do Bisphosphonates Reduce Cardiovascular-Related Mortality?

    May 13, 2021

    It is well known that hip fractures are associated with significant morbidity and mortality: Mortality increases 15–25% in the year following a hip fracture.1–5 We know that treating osteo­porosis prevents fractures and improves patient survival. But is there a relationship beyond this? Several studies have found that bisphosphonate therapy is associated with a reduction in…

    Psoriatic Arthritis Drugs at a Glance, 2023

    April 21, 2023

    Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    August 16, 2019

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    How to Optimize Treatment for Aging Patients with Rheumatic Conditions

    August 30, 2023

    As patients with rheumatic musculoskeletal disease age, the number of medications they take may increase (i.e., polypharmacy), which can result in unwanted side effects and serious adverse effects. Lee et al. offer considerations and insights into caring for aging patients in a polypharmacy situation to better meet their health and lifestyle needs.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences